Bio4Dreams’ first partial exit from BrainDTech

6 September 2024

Corporate

Portfolio

/

Bio4Dreams has completed its first partial exit from BrainDTech, achieving a 9x return on investment.

In March 2024, Bio4Dreams completed its first partial exit from the innovative SME BrainDTech. The exit generated a 9x return on investment and was finalized as part of a new capital increase of 1.5 million euros, set to conclude at the end of the year, which has already seen the entry of Bridge4Pharma into the company’s capital.

BrainDTech is developing an innovative diagnostic approach for precision medicine based on its proprietary technology, MicroCATCH, capable of reading a specific molecular signal from damaged tissue directly in liquid biopsy (blood or saliva). BrainDTech is applying this technology to identify innovative biomarkers in neurodegenerative diseases, such as Alzheimer’s, multiple sclerosis, and traumatic brain injury. It has been incubated and invested in by Bio4Dreams since 2018 and has so far raised about 3 million euros through capital increases and grants received.

In 2023, the SME established the joint venture BrainCode in the United States with American investors and venture builders to facilitate the entry of its solutions into the US market.

📈 See the investors page.

Altri aggiornamenti

11 Oct 24

Corporate

FDA grants orphan drug designation to ChemiCare’s drug candidate

Bio4Dreams’ first partial exit from BrainDTech

6 September 2024

Corporate

Portfolio

/

Bio4Dreams has completed its first partial exit from BrainDTech, achieving a 9x return on investment.

In March 2024, Bio4Dreams completed its first partial exit from the innovative SME BrainDTech. The exit generated a 9x return on investment and was finalized as part of a new capital increase of 1.5 million euros, set to conclude at the end of the year, which has already seen the entry of Bridge4Pharma into the company’s capital.

BrainDTech is developing an innovative diagnostic approach for precision medicine based on its proprietary technology, MicroCATCH, capable of reading a specific molecular signal from damaged tissue directly in liquid biopsy (blood or saliva). BrainDTech is applying this technology to identify innovative biomarkers in neurodegenerative diseases, such as Alzheimer’s, multiple sclerosis, and traumatic brain injury. It has been incubated and invested in by Bio4Dreams since 2018 and has so far raised about 3 million euros through capital increases and grants received.

In 2023, the SME established the joint venture BrainCode in the United States with American investors and venture builders to facilitate the entry of its solutions into the US market.

📈 See the investors page.

Altri aggiornamenti

11 Oct 24

Corporate

Bio4Dreams among the partner of Startup Breeze 2024

8 Oct 24

Corporate

Bio4Dreams joins CEBR, expanding its network across Europe

4 Oct 24

Portfolio

BiomimX: expands with new spaces at Bio4Dreams HQ

3 Oct 24

Corporate

Bio4Dreams partner of Unipa’s new hub for tech transfer

27 Sep 24

Portfolio

FDA grants orphan drug designation to ChemiCare’s drug candidate

Bio4Dreams’ first partial exit from BrainDTech

6 September 2024

Corporate

Portfolio

/

Bio4Dreams has completed its first partial exit from BrainDTech, achieving a 9x return on investment.

In March 2024, Bio4Dreams completed its first partial exit from the innovative SME BrainDTech. The exit generated a 9x return on investment and was finalized as part of a new capital increase of 1.5 million euros, set to conclude at the end of the year, which has already seen the entry of Bridge4Pharma into the company’s capital.

BrainDTech is developing an innovative diagnostic approach for precision medicine based on its proprietary technology, MicroCATCH, capable of reading a specific molecular signal from damaged tissue directly in liquid biopsy (blood or saliva). BrainDTech is applying this technology to identify innovative biomarkers in neurodegenerative diseases, such as Alzheimer’s, multiple sclerosis, and traumatic brain injury. It has been incubated and invested in by Bio4Dreams since 2018 and has so far raised about 3 million euros through capital increases and grants received.

In 2023, the SME established the joint venture BrainCode in the United States with American investors and venture builders to facilitate the entry of its solutions into the US market.

📈 See the investors page.

Altri aggiornamenti

11 Oct 24

Corporate

Bio4Dreams among the partner of Startup Breeze 2024

8 Oct 24

Corporate

Bio4Dreams joins CEBR, expanding its network across Europe

4 Oct 24

Portfolio

BiomimX: expands with new spaces at Bio4Dreams HQ

3 Oct 24

Corporate

Bio4Dreams partner of Unipa’s new hub for tech transfer

27 Sep 24

Portfolio

FDA grants orphan drug designation to ChemiCare’s drug candidate

Bio4Dreams’ first partial exit from BrainDTech

6 September 2024

Corporate

Portfolio

/

Bio4Dreams has completed its first partial exit from BrainDTech, achieving a 9x return on investment.

In March 2024, Bio4Dreams completed its first partial exit from the innovative SME BrainDTech. The exit generated a 9x return on investment and was finalized as part of a new capital increase of 1.5 million euros, set to conclude at the end of the year, which has already seen the entry of Bridge4Pharma into the company’s capital.

BrainDTech is developing an innovative diagnostic approach for precision medicine based on its proprietary technology, MicroCATCH, capable of reading a specific molecular signal from damaged tissue directly in liquid biopsy (blood or saliva). BrainDTech is applying this technology to identify innovative biomarkers in neurodegenerative diseases, such as Alzheimer’s, multiple sclerosis, and traumatic brain injury. It has been incubated and invested in by Bio4Dreams since 2018 and has so far raised about 3 million euros through capital increases and grants received.

In 2023, the SME established the joint venture BrainCode in the United States with American investors and venture builders to facilitate the entry of its solutions into the US market.

📈 See the investors page.